Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Investigational (Tier 3)GRADE: Low

Investigational / Research Priority

Gynecological applications of hirudotherapy are not included in FDA 510(k) clearance for medicinal leeches. All evidence below reflects international clinical experience. Gynecological use constitutes off-label application.

Investigational Application

Gynecology is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Gynecological applications represent one of the most extensively documented hirudotherapy domains, with data spanning six decades (1944-2003) and over 700 patients across 19 investigations. The evidence includes two controlled trials (Gelman, 1962, n=155; Khardikov et al., 2003, n=50) and one Western case report (Tissot-Guerraz et al., 1987). No randomized controlled trials exist for any gynecological indication.

Fundamento biológico

Inflammatory diseases of the female reproductive organs feature microvascular compromise within pelvic venous and lymphatic plexuses, peritoneal adhesion formation, and chronic tissue edema. Infection damages endothelial integrity, activates local coagulation, and impairs drainage, creating a self-perpetuating cycle of congestion, hypoxia, and fibrosis. Conditions such as endometriosis and tubal obstruction share overlapping vascular and fibrotic pathophysiology.

Anti-Inflammatory

Eglins and bdellins inhibit elastase, cathepsin G, trypsin, and plasmin, attenuating neutrophil-mediated tissue damage central to parametritis, adnexitis, and endometriosis.

Antimicrobial

Destabilase-L provides bactericidal lysozyme activity against gram-positive pathogens (S. aureus), relevant to puerperal infections, mastitis, and vaginal dysbiosis.

Decongestive

Hyaluronidase facilitates edema drainage and enhances tissue permeability, addressing lymphatic congestion that perpetuates chronic pelvic inflammation and adhesions.

Anticoagulant

Hirudin, calin, and saratin address the hypercoagulable microenvironment in pelvic inflammation, where microthrombosis contributes to tissue ischemia and fibrosis.

Analgesic

Kininases degrade bradykinin locally, providing analgesia particularly relevant to chronic pelvic pain and endometriosis-associated pain syndromes.

Anti-Adhesion

Hyaluronidase, proteinase inhibitors, and microcirculatory enhancement collectively target the adhesion cascade in tubal obstruction and endometriosis.

Evidencia clínica

Sixteen studies investigated gynecological hirudotherapy. All originate from Russian/Eastern European centers (1944-2003) except one French case report. The two controlled trials (Gelman, 1962; Khardikov et al., 2003) provide the strongest evidence.

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

Gynecology — International Clinical Evidence
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Gelman 1962	Controlled trial	Parametritis / adnexitis (n=155)	HT+penicillin (n=67) vs controls (n=88)	Sustained improvement at 12-18 mo	76% vs 25% sustained improvement Largest controlled gynecological trial
Khardikov et al. 2003	Controlled trial	Chronic salpingo-oophoritis (n=50)	HT+therapy (n=20) vs controls (n=30)	Blood flow, inflammatory resolution	80% vs 40% resolution (p<0.01)
Gromova 2000	Case series	Acute/chronic salpingo-oophoritis (n=70)	HT adjunct to pharmacotherapy	Pain, well-being, functional capacity	Accelerated recovery at all stages
Zhivoglyad & Nikonov 1998	Case series	Endometriosis (n=40)	12 sessions; up to 140 MLs per course	Ultrasound assessment	60% no residual endometriosis on US Min 102 MLs recommended
Startseva et al. 2001	Case series	Endometriosis (refractory) (n=41)	Intravaginal+external; 2-3 courses	Pain, blood loss, fertility	90% reduced bleeding; 4 pregnancies
Kurgina 2000	Case series	Bacterial vaginosis (n=28)	2-5 MLs q1-2d; 10-15 sessions	Clinical/microbiological cure	complete clinical response in all 28 patients; full lactobacillus restoration 11 monotherapy; 17 HT+metronidazole
Batoev 1999	Case series	Hydrosalpinx (prior failure) (n=20)	Monotherapy; 4-6 sessions	US assessment	80% undetectable; 20% decreased
Platonov 1998	Case series	Postpartum wounds/cesarean (n=95)	MLs to suture infiltrate sites	Infiltrate resolution	Good response; improved microcirculation
Galchenko & Shkolny 1969	Case series	Chronic adnexitis (n=25)	4-5 MLs posterolateral fornices	TEG, pain, mobility	TEG correction; increased mobility
Chaban et al. 1995	Mixed case series	Gynecological diseases (n=73)	HT+standard treatment	Clinical improvement	Effective; alternative to surgery for myomas
Tissot-Guerraz et al. 1987	Case report	Purulent mastitis (n=1)	ML application to breast	Infection resolution	Successful; antibacterial effect Only Western-published case

Parametritis y anexitis — Hallazgos detallados

The most extensively documented indication, with five studies spanning 1944-1969. Parametritis begins with infection penetrating venous and lymphatic plexuses, progressing to parametrial tissue involvement and potential abscess formation.

Gelman (1962) conducted the largest controlled trial: 3-5 leeches every 4-5 days to the vaginal fornix with 16-hour tamponade. At 12-18 months, 76% of the HT group showed sustained improvement versus 25% of controls. Shvets (1967) documented rapid improvement (temperature, pain, ESR) with no systemic coagulation effect. Galchenko & Shkolny (1969) provided objective TEG documentation of coagulation correction.

Salpingo-ooforitis — Hallazgos detallados

Khardikov et al. (2003) studied chronic salpingo-oophoritis: HT group (n=20) vs controls (n=30). HT produced more pronounced pelvic blood flow improvement (p<0.01). Resolution: 80% HT vs 40% controls; significant regression in 20% vs 50%; 10% of controls showed no improvement.

Gromova (2000) observed 70 patients with acute/chronic disease. HT accelerated pain relief, well-being improvement, and functional capacity restoration. Recommended at four stages: infiltrative, subsiding acute, chronic, and during complications.

Endometriosis — Hallazgos detallados

Zhivoglyad & Nikonov (1998)

Protocol: 12 sessions; up to 140 leeches (min 102)
Sites: Anal triangle, Petit's triangle, abdominal wall
Result: 60% no residual endometriosis on US; 40% improved

Startseva et al. (2001)

Protocol: 15-20 MLs/course, 10-12 days; 2-3 courses
Sites: Intravaginal (fornices) + external (pubic, perianal)
Result: 90% reduced bleeding; 4 infertile women conceived

Four previously infertile women with endometriosis conceived within 2-3 months of completing HT and delivered at term. Hemostasis monitoring confirmed intravaginal hemorrhage risk did not outweigh clinical benefit (Startseva et al., 2001).

Vaginosis bacteriana e hidrosalpinx

Bacterial Vaginosis — Kurgina (2000)

complete clinical response in all 28 patients (28/28) with complete lactobacillus restoration. Eleven monotherapy; 17 HT+metronidazole. Applied to vaginal mucosa, cervix, abdominal wall, coccyx, liver projection; 2-5 MLs q1-2d, 10-15 sessions. Suggests dysbiosis correction rather than pathogen suppression.

Hydrosalpinx — Batoev (1999)

80% undetectable on US (16/20) after 4-6 sessions of monotherapy; 20% showed decreased size. All patients had failed prior conventional treatments. Applied to perineum, fornices, anal rhombus, abdominal wall, sacrum.

Infertilidad, posparto y otras indicaciones

Infertility: Across four observations, 10/34 previously infertile women (29%) conceived: Gromova (2000) 5/12; Startseva et al. (2001) 4 endometriosis patients; Kurgina (2000) 1/3. Results support biological plausibility through adhesion resolution and microcirculation improvement.

Postpartum: Three studies (~165 patients) showed rapid infiltrate resolution, pain reduction, and reduced post-cesarean complications (Platonov 1998; Batoev 1999; Gazazyan & Khardikov 2003).

Mixed series: Chaban et al. (1995, n=73) concluded HT effective for inflammatory conditions and a rational surgical alternative for myomas. Tissot-Guerraz et al. (1987) resolved purulent mastitis via destabilase-L activity — the only Western-published gynecological HT case.

Protocolo clínico

Inflammatory Indications

Parametritis / adnexitis — adjunct to antimicrobials
Salpingo-oophoritis — adjunct to pharmacotherapy
Postpartum endometritis, suture infiltrates, metrophlebitis
Infected perineal tears / post-cesarean wounds
Purulent mastitis — adjunct to antimicrobials

Non-Inflammatory Indications

Bacterial vaginosis — monotherapy or adjunct
Hydrosalpinx — monotherapy after conventional failure
Endometriosis — pain, menstrual dysfunction, refractory
Tubal / endocrine infertility — adjunct
Uterine fibroids / myomas — adjunct or surgical alternative

Pre-Procedure

Microbiological diagnosis (cultures, bacterioscopy, vaginal pH); initiate antimicrobials as indicated
Baseline pelvic ultrasound for structural conditions
Complete coagulation profile; review anticoagulant/antiplatelet medications
CBC baseline for multi-session courses
Rule out pregnancy and pelvic malignancy

Application Sites

Vaginal fornices (posterior/lateral): Adnexitis, salpingo-oophoritis, endometriosis — proximity to adnexa
Anterior abdominal wall (suprapubic): Parametritis, endometriosis, postpartum — projection over pelvic organs
Cervix / vaginal mucosa: Bacterial vaginosis, cervicitis — direct mucosal contact
Perineum: Hydrosalpinx, endometriosis, perineal tears — perineal plexus access
Lumbosacral / sacrum / coccyx: Postpartum, endometriosis — reflex zone; pelvic lymphatic drainage
Anal rhombus / Petit's triangle: Hydrosalpinx, endometriosis — deep pelvic venous drainage
Inguinal fold: Postpartum — pelvic lymphatic/venous drainage
Right hypochondrium (liver): Vaginosis, hydrosalpinx — hepatic portal decongestive effect

Dosing Parameters

Standard: 2-7 leeches/session; full exposure; 1-2x/week (parametritis q4-5d; vaginosis q1-2d); 3-12 sessions per course
Endometriosis: 15-20 MLs per course over 10-12 days; 10-12 sessions; 2-3 repeat courses; up to 140 total MLs (min 102 for extensive disease)

Intravaginal application: Vaginal fornix tamponade after detachment; remove at 16 hours (Gelman, 1962). Strict asepsis; lithotomy positioning. Prophylactic Aeromonas coverage (fluoroquinolone or TMP-SMX) required.

Post-Procedure

Tamponade removal at 16 hours; monitor oozing (4 to 24 hours expected)
Follow-up ultrasound at course completion for structural conditions
Reassess pain, temperature, ESR, pelvic mobility every 2-3 sessions
CBC at mid-course and completion (cumulative blood loss detection)
Repeat cultures for bacterial vaginosis at course end

Consideraciones de seguridad

Pelvioperitonitis (ABSOLUTE): Risk of sepsis generalization and DIC; SGS anticoagulants exacerbate coagulopathy (Yakimova, 1999).
Acute septic endometritis (ABSOLUTE): Same DIC/sepsis risk. Distinguish treatable infiltrative/subacute stages from contraindicated septic states.
Active hemorrhage: SGS anticoagulant/antiplatelet properties exacerbate bleeding.
Pregnancy: Relative contraindication.
Suspected malignancy: Tissue diagnosis first; local application may enhance neoplasm blood flow.

Stage-Specific Risk

Indicated: Infiltrative stage (promotes resolution), subsiding acute (accelerates resolution), chronic course (addresses fibrosis and adhesions). Case-by-case: Complication stage (suppuration may respond; peritonitis contraindicated). Contraindicated: Acute septic phase and pelvioperitonitis (DIC/sepsis risk; Yakimova, 1999).

Drug Interactions

Medication	Interaction	Action
Anticoagulants	Additive (hirudin, calin, saratin, apyrase)	Careful monitoring; dose adjustment
Antiplatelet agents	Additive platelet inhibition	Individual risk-benefit assessment
Antimicrobials	No adverse interactions	Continue as indicated
Hormonal therapy / OCP	Theoretical estrogen-thrombotic concern	Standard precautions

Monitoring

Coagulation: Baseline and periodic (especially endometriosis extended courses)
CBC: Cumulative blood loss; critical for hyperpolymenorrhea patients
Ultrasound: Baseline and course completion for structural conditions
Clinical: Pain, temperature, ESR every 2-3 sessions
Microbiology: Repeat cultures for vaginosis at course end

Brechas de evidencia y prioridades de investigación

Despite 700+ patients across six decades, the evidence has significant limitations: no RCTs, all data from Russian/Eastern European centers, variable outcome measures, and combined interventions limiting attribution.

Chronic salpingo-oophoritis: RCT with pelvic Doppler and inflammatory markers
Bacterial vaginosis: Controlled comparison with microbiome analysis
Endometriosis pain: Pilot with VAS and EHP-30 endpoints
Hydrosalpinx: Prospective cohort with serial US and hysterosalpingography
Reproductive outcomes: Prospective fertility registry

In the United States, medicinal leeches are FDA-cleared (510k) for microsurgery venous congestion only. Gynecological applications constitute off-label use not evaluated by the FDA. Evidence consists of Level III-IV studies. No efficacy claims can be made for any gynecological indication.

Conclusiones clave

Controlled trial data: Three-fold improvement in parametritis (76% vs 25% at 12-18 mo) and two-fold in salpingo-oophoritis (80% vs 40%, p<0.01) across two non-randomized controlled trials.

Microbiome restoration: complete clinical response in all 28 patients with full lactobacillus restoration in bacterial vaginosis (n=28), suggesting dysbiosis correction rather than pathogen suppression.

Critical contraindications: Pelvioperitonitis and acute septic endometritis are absolute contraindications (DIC/sepsis risk). Stage-appropriate patient selection is fundamental.

Endometriosis protocols: Most intensive in the literature (up to 140 leeches, 12 sessions, 2-3 courses). 60% no residual US findings; 90% reduced bleeding; 4 pregnancies in infertile women.

Hydrosalpinx monotherapy: 80% undetectable on US after 4-6 sessions in patients who had failed all prior conventional treatments (n=20).

Investigational status: All gynecological applications are off-label in the US. Evidence is Level III-IV from Russian/Eastern European centers. RCTs needed.

Referencias

Batoev, Ts. Zh. (1999). Hirudotherapy in postpartum complications.
Batoev, Ts. Zh. (1999a). Hirudotherapy for hydrosalpinx (n=20).
Bornshtein, I. A. (1952). Leeches in acute pelvic inflammation.
Chaban, T. N., Kapralova, M. V., & Savinov, V. A. (1995). HT in 73 gynecological patients.
Galchenko, G. I., & Shkolny, V. N. (1969). TEG changes in chronic adnexitis.
Gazazyan, M. G., & Khardikov, A. V. (2003). HT after cesarean section.
Gelman, I. G. (1962). Comparative study in parametritis/adnexitis (n=155).
Gromova, O. A. (2000). HT in salpingo-oophoritis and infertility (n=70).
Khardikov, A. V., et al. (2003). Controlled study, chronic salpingo-oophoritis (n=50).
Kurgina, L. S. (2000). HT for bacterial vaginosis (n=28).
Lukyanova, E. A. (1999). HT for tubal infertility.
Platonov, A. V. (1998). HT in postpartum wound healing (n=95).
Shamilev, R. V., & Kulanin, G. V. (2001). Sanatorium gynecological HT.
Shpolyansky, B. A. (1944). HT in parametritis (n=15).
Shvets, V. N. (1967). Leeches in parametritis treatment.
Startseva, N. V., et al. (2001). HT for endometriosis (n=41).
Tissot-Guerraz, F., et al. (1987). Leech treatment of purulent mastitis.
Yakimova, T. P. (1999). Contraindications for gynecological HT.
Zhivoglyad, R. N., & Nikonov, G. I. (1998). HT for endometriosis (n=40).

Ginecología